Market Overview

Morgan Stanley Sees Another Solid Year Ahead for Becton, Dickinson and Co.

Share:
Related BDX
Benzinga's Top Upgrades
Earnings Scheduled For February 3, 2016
MedTech Series: Why Medical Technology Companies Should Have A Place In Your Portfolio (Seeking Alpha)

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Becton, Dickinson and Co. (NYSE: BDX).

In the report, Morgan Stanley noted, “Our more bullish tone into FY14 was driven by multi-year investments that have begun to impact top and bottom line results. We continue to expect modest upside through the year and see additional potential acceleration from generic injectables, diabetes, SG&A leverage, and M&A.”

Becton, Dickinson and Co. closed on Tuesday at $106.01.

Latest Ratings for BDX

DateFirmActionFromTo
Feb 2016Deutsche BankUpgradesHoldBuy
Feb 2016CitigroupMaintainsNeutral
Jan 2016Evercore ISI GroupDowngradesBuyHold

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BDX)

Get Benzinga's Newsletters